Policy Reversal: FDA Will No Longer Require Suffixes For Older Biologics
Executive Summary
New US FDA draft guidance says that the agency will no longer change the proper names of originator biologics to include a four-letter suffix, although the agency will continue to attach suffixes to future approvals.
You may also be interested in...
How Might FDA Be Convinced To Change Biosimilar Naming Policy?
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.
Biosimilar Competition: How Might FDA Be Convinced To Change Its Naming Policy?
Following FDA/FTC workshop, several stakeholders urge FDA to do away with suffixes for biosimilar names while others seek reconsideration of switching studies for interchangeability.
Biosimilars: Some Patient And Prescriber Groups Appear To Warm Up To Arbitrary Suffixes
Patient and prescriber groups were largely opposed to suffixes for the nonproprietary names of biological products being devoid of meaning when the US FDA first published its nomenclature policy, although a few of these groups may be signaling less of a worry than they once had.